icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
 
 
 
Preclinical antiviral drug combination studies utilizing novel orally bioavailable agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, an HBV RNA destabilizer
 
 
  full pdf slide presentation attached
 
Reported by Jules Levin
EASL - The International Liver Congress 2018,
April 11 -15, 2018, Paris, France
Rene Rijnbrand
Arbutus Biopharma Inc.
 
Download the PDF here
 

0427181

HBV

Source: Hepatitis B. WHO (2017) http://www.who.int/mediacentre/factsheets/fs204/en/

0427183

0427184

0427185

0427186

0427187

0427188

0427189